Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Geaney leaves as Elan CEO

Donal Geaney has departed as chairman and CEO of ELN and Thomas Lynch departed as vice chairman. Garo Armen, chairman and CEO of Antigenics (AGEN) and

Read the full 263 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE